T-cell mean telomere lengths changes in treatment naïve HIV-infected patients randomized to G-CSF or placebo simultaneously with initiation of HAART

Scand J Immunol. 2001 Sep;54(3):301-5. doi: 10.1046/j.1365-3083.2001.00935.x.

Abstract

The effect of highly active antiretroviral therapy (HAART) and granulocyte colony stimulating factor (G-CSF) on mean telomere restriction fragment (TRF) length of peripheral blood mononuclear cells (PBMC) was examined in 11 treatment naïve human immunodeficiency virus (HIV)-infected individuals with a CD4+ T-cell count < 350 cells/mm3. Patients were randomized to HAART combined with G-CSF thrice weekly for 12 weeks (n = 6) or placebo (n = 5). An increase in the mean TRF lengths was observed in PBMC of patients on HAART after 24 weeks of treatment mainly owing to increased mean CD8+ T-cell TRF lengths. However, in the group of patients on HAART combined with G-CSF no changes of PBMC mean TRF length was observed during treatment or during 12 weeks of follow-up. The mean CD4+ T-cell TRF length did not change in any of the two groups. These results confirm that HAART induces mainly the lengthening of the mean CD8+ T-cell TRF length. However, G-CSF given simultaneously with HAART induces an inhibition of the expected lengthening in mean TRF length. These results do therefore not support the use of adjuvant G-CSF treatment simultaneously when initiating HAART and should further be evaluated before use in non-neutropenic HIV-infected patients.

Publication types

  • Clinical Trial
  • Randomized Controlled Trial

MeSH terms

  • Antiretroviral Therapy, Highly Active*
  • CD4-Positive T-Lymphocytes / ultrastructure
  • CD8-Positive T-Lymphocytes / ultrastructure*
  • Drug Therapy, Combination
  • Female
  • Granulocyte Colony-Stimulating Factor / therapeutic use*
  • HIV Infections / drug therapy*
  • HIV Infections / genetics*
  • HIV Infections / immunology
  • Humans
  • Male
  • Telomere / ultrastructure*

Substances

  • Granulocyte Colony-Stimulating Factor